Emercell and Cell-Easy Sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001
Emercell SAS (Emercell) and Cell-Easy SAS (Cell-Easy) announced today the signing of a strategic agreement for the scale-up and manufacturing of Emercell’s lead product.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005449/en/
Emercell has developed a platform technology to produce off-the-shelf natural killer (NK) cells. NK cells are highly potent immune effectors, used alone as monotherapy, or in combination with therapeutic antibodies, or are genetically engineered to produce Chimeric Antigen Receptor (CAR)-NK cells for the treatment of hematological malignancies and solid tumors. NK-001 is an optimized cell therapy product composed of highly activated and alloreactive allogeneic NK cells. Its patented manufacturing process allows a complete industrialization by using the same batch of NK cells for multiple patients.
Cell-Easy is an analytics-driven Contract Development and Manufacturing Organization (CDMO) specialized in the production of Gene-modified Cell and Cell Therapy products. Cell-Easy’s facilities are located in Toulouse including state-of-the-art controlled environment suites optimized for developing manufacturing and analytical processes, proceed to environmental and material Quality Control, and execute cGMP manufacturing, fill & finish, long-term storage of Advanced Therapy Medicinal Products (ATMPs) compliant with all the requirements of regulatory standards and cGMP guidelines.
Emercell has selected Cell-Easy as a long-term CDMO partner for the scale-up and manufacturing operations of its allogeneic NK cell-based product, with the objective to enter clinical phase in 2023. Emercell has signed a strategic agreement with Cell-Easy specialized in the development and production of ATMP.
“We are very pleased to collaborate with Cell-Easy on the final stages of development and GMP manufacturing of our flagship product, NK-001“, said Patrick Henno, President of Emercell.” We are looking forward to a successful and long-lasting collaboration as a key element of our development strategy. Moreover, Cell-Easy and Emercell are located in the Occitanic Region and the partnership fits perfectly with the Region’s objectives regarding the development and production of new products in the field of biotherapies, and particularly in the field of immunotherapy.
In a very competitive European landscape, we are delighted that Emercell has chosen us as their privileged CDMO Partner for their first immune-oncology approach using NK-cells”, said Guillaume Costecalde, President of Cell-Easy. “Cell-Easy CDMAO’s original approach and the team’s reactivity combined with our state-of-the-art facility allow us once again to convince ambitious ATMP developers such as Emercell to secure their development.”
About Emercell
Emercell is an oncology company developing a platform technology to produce off-the-shelf allogenic natural killer (NK) cells. The company's R&D activities are located at the IRMB (Institute of Regenerative Medicine and Biotherapies) at the Saint-Éloi University Hospital Center, Montpellier, France. Emercell's lead drug candidate, NK-001, is intended, among others, for the treatment of lymphoma patients who are refractory to conventional therapies. It is a patented process for pre-activating and amplifying allogeneic NK cells. Emercell collaborates with numerous industrial and academic partners. The company has received the support of the Occitanie Region (ADI) and Bpifrance and has obtained a FUI (financing). Emercell is a member of Eurobiomed.
About Cell-Easy
Cell-Easy developed a unique vision of CDMO dedicated to the production of Cell and Gene modified Cell Therapy products. This integrated concept is called CDMAO. Beyond CDMO, CDMAO is not only focused on Development & Manufacturing. CDMAO is positioned as a real partner for helping Biotech & Pharma to bridge the gap between preclinical and clinical development with in-depth expertise on regulatory process scale-up and analytics.
Cell-Easy offers customized process development, process scale-up, cGMP manufacturing and unique analytical services for immune cells (engineered CAR-T, NK, …cells, and non-engineered cells) and adult stem cells (MSCs, iPSCs and Exosomes) both in Immuno-Oncology and Regenerative Medicine fields.
Cell-Easy is a trusted partner and brings today the infrastructure and know-how while ensuring your projects are delivered on time and budget. Supported by highly motivated and experienced people in the Cell Therapy field, Cell-Easy is committed to driving service excellence and actively contribute to a “Bench to Bedside” culture, putting the healthcare of patients at the center of everything.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005449/en/
Contact information
Media and Investor Contacts:
Emercell, Dr. Patrick Henno, President, patrick.henno@emercell.com, (+33)-6-14-77-39-21
Cell-Easy, Dr. Guillaume Lay, Business Development, Guillaume.lay@cell-easy.com, (+33)-6 15 18 13 13
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Veridas Identity Fraud Solutions Now Available on AWS Marketplace21.8.2025 19:05:00 EEST | Press release
Veridas, a global leader in identity verification and biometric solutions, today announced that its Identity Verification (IDV) platformis now available on Amazon Web Services (AWS) Marketplace. This launch puts the full power of Veridas’ fraud prevention and identity verification capabilities in the hands of millions of AWS customers worldwide, making secure digital trust only a click away. As identity fraud rises exponentially — with threats from synthetic identities, deepfakes, and injection attacks — Veridas delivers a cloud-native solution combining facial biometrics, AI-driven document authentication, and certified liveness detection. The platform shields enterprises from fraud while enabling seamless onboarding in seconds. “Live since 2017, our IDV platform already protects more than 300 clients in 25 countries against advanced fraud such as deepfakes and injection attacks, with 100% proprietary technology, global coverage, and international compliance,” said Eduardo Azanza, CEO
Altasciences Chosen by Steel Therapeutics to Support the Launch of Pivotal Toxicology Study for Fizurex™21.8.2025 18:21:00 EEST | Press release
Altasciences is pleased to have been chosen by Steel Therapeutics, Inc. (“Steel”), to initiate a pivotal toxicology study for Fizurex™, a novel topical therapy for the treatment of anal fissures. The GLP-compliant study is currently being conducted at Altasciences’ preclinical facility in Columbia, MO. It marks a key milestone in Steel’s regulatory development, as the company prepares for an Investigational New Drug (IND) application in early 2026. “We’re proud to be supporting Steel Therapeutics at this key stage of their development journey,” said Steve Mason, Co-COO at Altasciences. “Our teams are aligned in their commitment to accelerate the delivery of patient-centered therapies. The initiation of this study is another example of how early collaboration and scientific rigor can bring important treatments closer to market.” Fizurex™, a patent-pending compounded wipe, has seen widespread use in clinical practice and is now progressing through the formal regulatory pathway to reach b
Media alert | Masdar receives ‘AA-’ credit rating with stable outlook by S&P Global Ratings in further recognition of the financial strength of the business21.8.2025 16:55:00 EEST | Press release
Masdar has been assigned an ‘AA-’ credit rating with a stable outlook by S&P Global Ratings, reinforcing its position as a global clean energy leader. This new rating reflects Masdar's diversified global position, strong growth prospects, and disciplined financial policies, including the allocation of green bond proceeds to finance the construction of new projects. With top credit ratings now secured from Moody’s (A1), Fitch (AA-) and S&P (AA-), Masdar continues to be recognized as one of the most financially robust renewable energy companies worldwide. This enables the Company to continue to drive responsible expansion and deliver inclusive progress across key international markets. The rating is also underpinned by the strong support of the Company's three shareholders - Abu Dhabi National Oil Company (ADNOC), Mubadala Investment Company, and Abu Dhabi National Energy Company PJSC (TAQA) - as well as the Government of Abu Dhabi. View source version on businesswire.com: https://www.bu
Andersen Consulting Expands Presence Through Collaboration with Ignis21.8.2025 16:30:00 EEST | Press release
Andersen Consulting adds depth to its strategy capabilities with collaborating firm Ignis, a leading media agency, reinforcing the organization’s commitment to delivering seamless solutions to clients globally. Founded in Buenos Aires, Ignis has earned a reputation for helping organizations build and achieve their brand objectives. With expertise in marketing communications strategy, market research, media planning and buying, and digital marketing, the firm works with companies in industries such as banking, insurance, and food and beverage across Latin America to drive brand growth, customer engagement, and measurable business results. “We’ve built Ignis with a spirit of entrepreneurship and bold thinking, and this collaboration enhances the global reach and resources to continue scaling that vision,” said Alejandro Terzi, chairman and founder of Ignis. “It opens new doors for innovation, fuels our ability to take on more ambitious challenges, and ultimately, allows us to deliver eve
Verb Technology Announces $780 Million in Treasury Assets to Advance its TON Treasury Strategy21.8.2025 16:20:00 EEST | Press release
Verb Technology Company, Inc. (Nasdaq: VERB) (to be renamed Ton Strategy Company) (the “Company”) today announced treasury assets exceeding $780 million, including $713 million1 of Toncoin ($TON), the native cryptocurrency of The Open Network (“TON”) Blockchain, and $67 million of cash. This is an important milestone in the Company’s implementation of its previously announced $TON treasury strategy. Today’s news follows the Company’s August 8 closing of a $558 million private placement joined by more than 110 institutional and crypto-native investors. The Company used the majority of proceeds from the private placement to acquire $TON as its primary treasury reserve asset. "Crossing $780 million in assets just days after our private placement reflects the conviction behind $TON,” said Manuel Stotz, Executive Chairman of the Company. “This is more than building a balance sheet; it’s about contributing to the security of TON blockchain – where participants can build, transact, and benefi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom